The Epidermolysis Bullosa Pipeline Insight report from DelveInsight offers a detailed overview of the pipeline therapies in various clinical and preclinical stages of growth, their introduction, and how the Epidermolysis Bullosa market is expected to change as a result.
Some of the Crucial Highlights from the Epidermolysis Bullosa Pipeline Report
Request for sample @ Epidermolysis Bullosa Pipeline Insight and Outlook
The Epidermolysis Bullosa Pipeline Analysis report provides a 360-degree view of the therapeutics environment for Epidermolysis Bullosa evolving therapies, including development stage, product type, route of administration, molecule type, and MOA.
The pipeline report covers everything from business opportunities to challenges to future partnerships to strong rivals to growth strategies.
Epidermolysis Bullosa: Disease Overview
Epidermolysis Bullosa is a group of rare diseases that cause the skin to become brittle and blistered. Blisters may form as a result of minor trauma, such as fire, rubbing, scratching, or adhesive tape. Blisters may appear anywhere on the skin’s surface, inside the oral cavity, and in more extreme cases, the external surface of the eye, as well as the respiratory, gastrointestinal, and genitourinary tracts.
Read more about Epidermolysis Bullosa
Epidermolysis Bullosa: Symptoms
Symptoms of Epidermolysis Bullosa includes:
Epidermolysis Bullosa: Treatment
Epidermolysis Bullosa has no known cure. Epidermolysis Bullosa is currently treated with symptomatic cures. The main goal is to protect the skin and prevent blisters from forming, as well as to encourage healing and avoid complications. Gene therapy and cell-based therapy are among the treatments in clinical trials to improve quality of life.
To learn more about disease, causes and treatment visit, Epidermolysis Bullosa Pipeline Landscape
Epidermolysis Bullosa Pipeline Analysis: Drug Profile
B-VEC: Krystal Biotech
B-VEC is a replication-deficient HSV-1 vector with two functional COL7A1 genes that can be applied topically. B-VEC (Beremagene Geperpavec, formerly “KB103”) is a non-integrating viral vector based gene therapy that was engineered using Krystal’s Skin TARgeted Delivery platform, or STAR-D platform, to deliver functional human COL7A1 genes directly to patients’ dividing and non-dividing skin cells.
Key Pipeline Therapies and Major Pharmaceutical Companies
Gain more knowledge on emerging drugs @ Epidermolysis Bullosa Pipeline Therapies
Epidermolysis Bullosa Therapeutics Assessment
Reach out for more information @ Epidermolysis Bullosa Pipeline Assessment
Scope of the Report
Coverage: Global
Key Players: Abeona Therapeutics, Phoenix Tissue Repair, Berg Pharma, Zikani Therapeutics, among others.
Key Pipeline Therapies: EB 101, PTR-01, Ubidecarenone, Ribosomal Modulators, others.
Table of Contents
1. | Introduction |
2. | Executive Summary |
3. | Epidermolysis Bullosa: Overview |
4. | Epidermolysis Bullosa Pipeline Therapeutics |
5. | Epidermolysis Bullosa Late Stage Products (Pre-registration) |
6. | Epidermolysis Bullosa Late Stage Products (Phase III) |
7. | Epidermolysis Bullosa Mid Stage Products (Phase II) |
8. | Epidermolysis Bullosa Early Stage Products (Phase I) |
9. | Epidermolysis Bullosa Pre-clinical and Discovery Stage Products |
10. | Epidermolysis Bullosa Therapeutic Assessment |
11. | Epidermolysis Bullosa Inactive Products |
12. | Epidermolysis Bullosa: Unmet Needs |
13. | Epidermolysis Bullosa: Market Drivers and Barriers |
14. | Appendix |
15. | About DelveInsight |
Know more of what’s covered in the Epidermolysis Bullosa Pipeline Assessment Report
Key Questions Answered in the Epidermolysis Bullosa Report
Request for a Webex demo @ Epidermolysis Bullosa Pipeline and get a walk-through of our report
Related Reports
Refractory Status Epilepticus Pipeline Insights
DelveInsight’s “Refractory Status Epilepticus – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Refractory status epilepticus pipeline landscape.
“Epilepsy Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Epilepsy market.
Dystrophic Epidermolysis Bullosa Pipeline Insights
“Dystrophic Epidermolysis Bullosa Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Dystrophic Epidermolysis Bullosa market.
Recessive Dystrophic Epidermolysis Pipeline Insights
“Recessive Dystrophic Epidermolysis (RDEB) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Recessive Dystrophic Epidermolysis (RDEB) market.
Drug Resistant Epilepsy Pipeline Insights
“Drug Resistant Epilepsy Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Drug Resistant Epilepsy market.
Epithelial Ovarian Cancer Pipeline Insights
“Epithelial Ovarian Cancer Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Epithelial Ovarian Cancer market.
Pre-Eclampsia Pipeline Insights
Get comprehensive analysis of Pre-Eclampsia pipeline therapies and key companies including Pharming Group, MirZyme, Amag Pharmaceuticals, Kyowa Kirin Co., Ltd, among others.
Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insights
Get comprehensive analysis of Relapsed or Refractory Myelodysplastic Syndrome pipeline therapies and key companies including such as Novartis, BioTheryX, Cantex Pharmaceuticals, Agios Pharmaceuticals, among others.
Lymphatic Malformations Pipeline Insights
Get comprehensive analysis of Lymphatic Malformations pipeline therapies and key companies including Vanthera, Cerecor, Inc., Protara therapeutics, among others.
Necrobiosis Lipoidica Pipeline Insights
Get comprehensive analysis of Necrobiosis Lipoidica pipeline therapies and key companies including Novartis, Processa Pharmaceuticals, among others.
Get in touch with our Business executive @ Rare Disease Market Insights to know more
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187
Connect With Us at: